9IRB image
Deposition Date 2024-07-15
Release Date 2025-08-20
Last Version Date 2025-08-20
Entry Detail
PDB ID:
9IRB
Title:
CryoEM structure of hSLC15A4+Fab107
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Mus musculus (Taxon ID: 10090)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.15 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Solute carrier family 15 member 4
Gene (Uniprot):SLC15A4
Chain IDs:A
Chain Length:602
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Fab107 heavy chain
Chain IDs:B (auth: H)
Chain Length:123
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:Fab107 light chain
Chain IDs:C (auth: L)
Chain Length:107
Number of Molecules:1
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Development of conformation-selective antibodies targeting human SLC15A4.
Nat Commun 16 7324 7324 (2025)
PMID: 40781080 DOI: 10.1038/s41467-025-62759-x

Abstact

SLC15A4, an endolysosomal solute carrier family transporter, plays a critical role in TLR7/8/9-induced immune responses through assembling a complex with the downstream adaptor TASL in a conformation-dependent manner. Despite its close functional association and promising therapeutic potential in infections, tumors, and autoimmune diseases, the development of conformation-specific antibodies for human SLC15A4 (hSLC15A4) remains challenging. Here, using a systematic screening and validation approach, we identify a pair of conformation-selective antibodies, clones 107 and 235, targeting the endolysosomal lumen surface of hSLC15A4 with opposite conformation-regulatory activities. Specifically, clone 107 selectively binds to hSLC15A4 in a TASL binding-incompetent luminal-open state; whereas clone 235 stabilizes hSLC15A4 in a TASL binding-competent cytoplasmic-open state. Our research identifies antibodies that recognize distinct conformations of hSLC15A4, potentially enabling modulation of the TLR7/8/9 pathway and contributing to the development of targeted therapies and research tools selectively targeting hSLC15A4.

Legend

Protein

Chemical

Disease

Primary Citation of related structures